Has Robert Alter, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,507,869 in general payments to Robert Alter, MD across 1,623 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Robert Alter, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Robert Alter, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Robert Alter, MD

Medical Oncology · Hackensack, NJNPI 1306805460

Payments from drug & device makers

$4,507,869in general payments, 2019–2025

Across 1,623 payments — averaging $2777.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$2.2M
Pfizer$1.1M
Seagen Inc.$476K
Eisai Inc.$99K
Exelixis Inc.$97K
E.r. Squibb & Sons, L.L.C.$90K
plus $429K from 52 others

$1,270in research payments, 2019–2025

Across 2 payments — averaging $635.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$1K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	372	$2,196,025
Pfizer	164	$1,120,321
Seagen Inc.	55	$476,306
Eisai Inc.	133	$98,759
Exelixis Inc.	42	$97,447
E.r. Squibb & Sons, L.L.C.	65	$90,405
Incyte Corporation	82	$60,492
Genentech, Inc.	30	$56,837
Bayer	95	$54,904
AstraZeneca(2 entities)	41	$44,152
Astellas Pharma US Inc	114	$34,414
Astellas Pharma Global Development	31	$33,038
EMD Serono, Inc.	39	$22,607
Clovis Oncology, Inc.	8	$20,564
Novartis	45	$20,432
Johnson & Johnson(2 entities)	101	$20,200
Sumitomo Pharma America, Inc.	7	$20,115
Takeda Pharmaceuticals U.S.A., Inc.	8	$14,935
Gilead	29	$7,192
Janssen Research & Development, LLC	5	$4,545
Astrazeneca UK Limited	1	$3,668
Regeneron Healthcare Solutions, Inc.	18	$2,595
AVEO Pharmaceuticals, Inc.	8	$1,742
Myovant Sciences Inc.	8	$1,057
Blueprint Medicines Corporation	2	$881
Blue Earth Diagnostics	1	$875
Janssen Scientific Affairs, LLC	1	$758
Foundation Medicine, Inc.	17	$363
Amgen	10	$362
Sanofi	14	$214
Fennec Pharmaceuticals, Inc.	4	$184
Dendreon Pharmaceuticals LLC	9	$162
Eli Lilly	2	$137
Daiichi Sankyo Inc.	9	$127
Lilly USA, LLC	7	$112
Sun Pharmaceutical Industries Inc.	6	$101
Comsort, Inc	1	$100
Progenics Pharmaceuticals, Inc.	3	$98
Sanofi-aventis U.S. LLC	1	$75
Bristol Myers Squibb	5	$73
Pharmacosmos Therapeutics Inc.	4	$70
Apellis Pharmaceuticals, Inc.	4	$66
Taiho Oncology, Inc.	3	$56
Genentech USA, Inc.	3	$43
Ipsen Biopharmaceuticals, Inc	2	$38
Caris MPI, Inc.	1	$31
Verity Pharmaceuticals Inc.	1	$29
Sobi, Inc	1	$19
AbbVie	1	$17
Jazz Pharmaceuticals Inc.	1	$17
Tempus AI, Inc	1	$17
Array Biopharma Inc	2	$16
Beone Medicines USA, Inc.	1	$16
Servier Pharmaceuticals LLC	1	$14
Amneal Pharmaceuticals LLC	1	$14
Rigel Pharmaceuticals, Inc.	1	$13
Tolmar Pharmaceuticals, Inc.	1	$12
Fortovia Therapeutics, Inc.	1	$8

How this compares

$4,507,869 in reported general payments places this provider in the 90th percentile of 112 medical oncology providers in New Jersey.

See all medical oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024

$1,133,714

Medicare patients

800

Services billed

43,309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Hackensack

Martin GutierrezHackensack$41.8M
James McCloskeyHackensack$17.1M
Lori LeslieHackensack$11.9M
Tatyana FeldmanHackensack$8.4M
David SiegelHackensack$6.9M
Noa BiranHackensack$5.8M
Andrew PecoraHackensack$4.5M
Jamie KoprivnikarHackensack$3.8M
David VesoleHackensack$3M
Deena GrahamHackensack$2.7M

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →